| 熊建,屈战利,任瑜,季一飞.阿加曲班对合并HHcy急性脑梗死患者血脂、炎症指标及神经系统功能的影响.[J].中南医学科学杂志.,2024,(4):563-566. |
| 阿加曲班对合并HHcy急性脑梗死患者血脂、炎症指标及神经系统功能的影响 |
| Effects of argatroban on blood lipids, inflammatory markers, and neurological function in patients with acute cerebral infarction complicated with hyperhomocysteinemia |
| 投稿时间：2023-06-12 修订日期：2024-05-21 |
| DOI：10.15972/j.cnki.43-1509/r.2024.04.013 |
| 中文关键词: 阿加曲班 急性脑梗死 高同型半胱氨酸血症 |
| 英文关键词:argatroban acute cerebral infarction hyperhomocysteinemia |
| 基金项目:四川省自然科学基金(2022NSFSC0756) |
|
| 摘要点击次数: 153 |
| 全文下载次数: 145 |
| 中文摘要: |
| 目的研究阿加曲班对合并高同型半胱氨酸血症(HHcy)急性脑梗死患者血脂、炎症指标及神经系统功能的影响。 方法选取140例合并HHcy的急性脑梗死患者,随机均分为对照组(常规治疗)和观察组(阿加曲班+常规治疗)。分析各组血浆同型半胱氨酸(Hcy)、高敏C反应蛋白(hs-CRP)、高密度脂蛋白胆固醇(HDLC)、低密度脂蛋白胆固醇(LDLC)、总胆固醇(TC)、甘油三酯(TG)、美国国立卫生研究院卒中量表评分(NIHSS)、日常生活活动能力评分量表(Barthel指数)、凝血酶原时间(PT)及活化部分凝血活酶时间(APTT)水平。分析治疗前Hcy、hs-CRP、HDLC、LDLC、TC、TG与NIHSS评分和Barthel指数的相关性。 结果与治疗前比较,治疗后对照组和观察组血Hcy、hs-CRP、LDLC及TC均下降,且观察组低于对照组(P＜0.05)。对照组PT、APTT于第5天升至正常范围,观察组于第3天即升至正常范围。在入院第2~4天时,观察组PT、APTT均明显高于对照组(P＜0.05),而第6~7天两组PT、APTT比较差异无显著性(P＞0.05)。与第1天比较,第7、30、90天两组NIHSS评分均降低,Barthel指数均升高；且观察组较对照组变化更为显著(P＜0.05)。血Hcy水平、hs-CRP、LDLC与NIHSS呈正相关,与Barthel指数呈负相关(P＜0.05)。 结论阿加曲班可显著降低HHcy急性脑梗死患者血脂、Hcy及炎症水平,改善患者凝血功能,加快神经功能及生活能力恢复。 |
| 英文摘要: |
| AimTo investigate the impact of argatroban on lipid profiles, inflammatory markers, and neurological function in acute cerebral infarction patients with hyperhomocysteinemia (HHcy). MethodsA total of 140 acute cerebral infarction patients with HHcy were selected and randomly divided into two groups, namely the control group (standard treatment) and the observation group (argatroban+standard treatment). We analyzed plasma homocysteine (Hcy), hyper-sensitivity C-reactive protein (hs-CRP), high density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDLC), total cholesterol (TC), triglycerides (TG), national institutes of health stroke scale (NIHSS) scores, Barthel index scores, prothrombin time (PT), and activated partial thromboplastin time (APTT). We then analyzed the correlation between Hcy, hs-CRP, HDLC, LDLC, TC, TG, NIHSS scores, and Barthel index before treatment. ResultsCompared with the pre-treatment levels, post-treatment levels of Hcy, hs-CRP, LDLC, and TC were decreased in both groups, with the observation group showing significantly lower levels than the control group (P＜0.05). PT and APTT returned to normal ranges by day 5 in the control group and by day 3 in the observation group. PT and APTT were significantly higher in the observation group than in the control group on days 2-4 (P＜0.05), but no significant differences were observed between the two groups on days 6-7 (P＞0.05). NIHSS scores were decreased and Barthel index scores were increased on days 7,30, and 90 in both groups compared with those on day 1, with more significant improvements in the observation group (P＜0.05). Hcy, hs-CRP, and LDLC levels were positively correlated with NIHSS scores and negatively correlated with Barthel index scores (P＜0.05). ConclusionArgatroban significantly reduces lipid levels, Hcy, and inflammation in acute cerebral infarction patients with HHcy, improves coagulation function, and accelerates the recovery of neurological function and daily living activities. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|